Updates are available Correction dated 2022-03-01
Click to view Correction: https://0-doi-org.brum.beds.ac.uk/10.1186/s12916-022-02306-3
-
Authors
Weerasuriya, Chathika K
Harris, Rebecca C
McQuaid, C Finn
Bozzani, Fiammetta
Ruan, Yunzhou
Li, Renzhong
Li, Tao
Rade, Kirankumar
Rao, Raghuram
Ginsberg, Ann M
Gomez, Gabriela B
White, Richard G
-
Funding
Funding for this research was provided by:
Medical Research Council (MR/N013638/1)
Aeras Global Tuberculosis Vaccine Foundation
- License Information
-
More Information
Article History
Received: 12 October 2020
Accepted: 29 January 2021
First Online: 26 February 2021
Change Date: 1 March 2022
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://0-doi-org.brum.beds.ac.uk/10.1186/s12916-022-02306-3
Ethics approval and consent to participate
: Not applicable
: Not applicable
: GBG reports currently being employed at Sanofi Pasteur. RCH reports currently being employed at Sanofi Pasteur. RCH reports grants from IAVI, during the conduct of the study; personal fees from Sanofi Pasteur, unrelated to TB and outside the submitted work. Sanofi Pasteur did not provide funding for this work and had no role in study design, data collection, data analysis, data interpretation, or writing of the report. AG reports grants from Bill and Melinda Gates Foundation, grants from UK DFID, during the conduct of the study; and during this period, Aeras and IAVI (AG’s employers during the time period) conducted TB vaccine clinical trials in collaboration with Sanofi and with GSK. However, neither paid any funds directly to AG or to Aeras or IAVI. All other authors declare no competing interests.
